COMP <GO>
ONC vs UNH // EV/EBITDA & P/E VALUATION
BeOne Medicines Ltd. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ONC 6
— UNH 8
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $371.56 (-0.48%) • MKT CAP: $42.25B
valuation
63.9x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | 88.57% | -1.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 11.47% | -0.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 63.9x | 16.4x | +47.45 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.23% | 6.48% | -4.25 | UNH | /fcf-yield <GO> |
| Operating Margin | 8.40% | 4.82% | +3.58 | ONC | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 3.14% | +2.26 | ONC | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 6.46% | +33.74 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 3.12 | +3.56 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 59.2 | -5.60 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.33 | +0.65 | ONC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 123.6x | 17.1x | +106.51 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $368.83B | -$326.58B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | UNH REV | ONC GROSS % | UNH GROSS % | ONC FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $447.57B | 87.5% | 88.7% | $941.7M | $16.07B |
| FY 2024 | $3.81B | $400.28B | 84.4% | 88.3% | -$633.3M | $20.70B |
| FY 2023 | $2.46B | $371.62B | — | 89.6% | -$1.27B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
UNH // BETA 0.33